002393 力生制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.0887.8212.1372.8030.200
总资产报酬率 ROA (%)1.7306.5361.7862.3910.167
投入资产回报率 ROIC (%)1.9697.4032.0252.6510.187

边际利润分析
销售毛利率 (%)56.16059.39857.58958.37961.475
营业利润率 (%)16.21636.40910.29712.5382.720
息税前利润/营业总收入 (%)11.21731.2704.4494.5790.287
净利润/营业总收入 (%)13.60131.3818.16411.1820.755

收益指标分析
经营活动净收益/利润总额(%)94.83343.668124.28394.316253.015
价值变动净收益/利润总额(%)3.4303.83720.24414.03752.323
营业外收支净额/利润总额(%)-0.0940.0970.2530.155-0.316

偿债能力分析
流动比率 (X)3.4954.5013.5974.2654.464
速动比率 (X)3.1904.2193.3243.8513.990
资产负债率 (%)18.46115.17417.79715.0340.143
带息债务/全部投入资本 (%)1.0540.4250.8340.1750.984
股东权益/带息债务 (%)8,911.46222,287.93511,341.69354,114.9219,574.399
股东权益/负债合计 (%)438.805559.003461.884565.143597.441
利息保障倍数 (X)-2.250-6.044-0.757-0.574-0.118

营运能力分析
应收账款周转天数 (天)40.56625.41041.02946.23350.121
存货周转天数 (天)120.764144.350158.398184.941211.587